International Stem Cell Corporation (ISCO) Continues Upward Climb with Two Successful Subsidiaries
A pioneer in regenerative medicine, International Stem Cell Corporation (OTCQB: ISCO) strives to make a difference with its stem cell technology called parthenogenesis. The biotechnology company uses unfertilized eggs to create pluripotent human parthenogenetic stem cells (hPSC). These stem cells have the power to turn into any cell, healing and replacing aged or damaged cells. The possible indications for this technology range from cellular treatment point to a breakthrough for the treatments of degenerative diseases of the eye, nervous system, and liver. ISCO’s research and development team strongly believe in the effectiveness of their stem cell solution in such diseases as Parkinson’s, Corneal Blindness, and Ischemic Stroke. However, completing the proper testing and sanctions necessary to commercialize the company’s technology will take many years. In the meantime, ISCO derives substantial revenue from its two subsidiaries: Lifeline Skin Care Inc. and Lifeline Cell Technology, LLC.
Lifeline Skin Care Inc.(www.lifelineskincare.com) focuses on developing and marketing anti-aging products using ISCO’s breakthrough stem cell technology. The cosmetic company uses stem cells from unfertilized eggs to create solutions that reverse aging, add elasticity, and improve damaged skin cells. First, proteins are captured from these eggs and encased in micro nanospheres for protection. Antioxidants, vitamins, and minerals are then added for extra rejuvenation. Lifeline Skin Care’s products boost collagen production for even, firm skin. Retailers like Amazon (NASDAQ: AMZN), cosmetic surgery offices, spas, and international corporations sell these products, which adds more revenue streams and exposure for ISCO.
ISCO’s other subsidiary, Lifeline Cell Technology, LLC. (www.lifelinecelltech.com), develops and commercializes human cell culture products. Academic, pharmaceutical, and government laboratories purchase these products, such as frozen human cells and the material need for cultivation, for disease testing and study. Lifeline Cell Technology offers epithelial, hematopoietic, bladder, breast, kidney cells and more with the highest guaranteed quality. According to the company, these cells will “out-perform any other cells” out there.
Though ISCO eagerly waits for its proprietary parthenogenesis technology to gain global allowance, the company effectively uses its two subsidiaries for a steady revenue stream. The operating income for both companies increased 65% to $1.67 million in 2015, with 2014 having $1.01 million. Lifeline Skin Care retained steady numbers while Lifeline Cell Technology sales were up 15%. Overall, ISCO saw an 8% increase last year, as compared to 2014. The company intends to continue using its scientific breakthroughs and products toward contributing to regenerative medicine.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at https://disclaimer.missionir.com